Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study

Authors: Pierfrancesco Tassone, Maria Teresa Di Martino, Mariamena Arbitrio, Lucia Fiorillo, Nicoletta Staropoli, Domenico Ciliberto, Alessia Cordua, Francesca Scionti, Bernardo Bertucci, Angela Salvino, Mariangela Lopreiato, Fredrik Thunarf, Onofrio Cuomo, Maria Cristina Zito, Maria Rosanna De Fina, Amelia Brescia, Simona Gualtieri, Caterina Riillo, Francesco Manti, Daniele Caracciolo, Vito Barbieri, Eugenio Donato Di Paola, Adele Emanuela Di Francesco, Pierosandro Tagliaferri

Source: Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-12 (2023)

Subject Terms: miRNA therapeutics, microRNA, miRNA, RNA therapeutics, Non-coding RNA therapeutics, miR-221, Diseases of the blood and blood-forming organs, RC633-647.5, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1756-8722

Access URL: https://doaj.org/article/4d9a753abc2e49c2bbde30064f04d177